Marwan Hariz, MD, PhD and Jordan P. Amadio, MD, MBA
Deep brain stimulation (DBS) for enhancements of non-disease states is ethically indefensible given our incomplete knowledge of this technology. Attention should instead be focused on increasing access to DBS for patients with illnesses potentially treatable by the procedure.
J. Brian Szender, MD, MS and Shashikant B. Lele, MD
The estimated reduction in risk of ovarian cancer for any woman undergoing opportunistic removal of the Fallopian tubes is up to 50 percent, but whether removal is more beneficial than ligation has not been established.
AMA J Ethics. 2015;17(9):843-848. doi:
10.1001/journalofethics.2015.17.9.stas1-1509.
Concerns about the deleterious effects of stress on the mind and body have led to the beginnings of a stress vaccine, an injection that will reduce these effects.
The AMA Code of Medical Ethics' opinions on confidential care for sexually active minors and physicians' exercise of conscience in refusal of services.
David Elkin, MD, Erick Hung, MD, and Gilbert Villela, MD
The rapidly evolving field of neuroethics is concerned with the ethical questions that new technologies will pose about autonomy, privacy, the definition of normal, and individuality.
During the 1960s and '70s, the iconography of ads for antipsychotic drugs changed from former depictions of docile white women patients to depictions of hostile black men, reflecting transformations in how American culture viewed race and mental illness.
Jonathan M. Metzl, MD, PhD and Dorothy E. Roberts, JD
The call for structural competency encourages medicine to broaden its approach to matters of race and culture so that it might better address both individual-level doctor and patient characteristics and institutional factors.
This month theme issue editor, Trahern Jones, a fourth-year student at Mayo Medical School in Rochester, Minnesota, spoke with Dr. Edward Laskowski about the use of performance-enhancing drugs and substances among athletes today.